Safe Use of Benzodiazepines: Clinical, Regulatory, and Public Health Perspectives

Public Meeting | July 12 & 13, 2021

In September 2020, the U.S. Food and Drug Administration announced a requirement that the Boxed Warning and other sections of benzodiazepine drug products’ labeling be updated to provide a more comprehensive description of risks related to nonmedical use, addiction, physical dependence, and withdrawal reactions. Benzodiazepine nonmedical use is widespread, and individuals frequently co-use benzodiazepines with alcohol, prescription opioids, and illicit drugs. Associated harms of benzodiazepine nonmedical use are substantial but occur primarily when people use benzodiazepines in combination with other drugs.

This two-day public workshop will convene regulators, academic researchers, clinicians, patient advocates, and other stakeholders to share information underlying this action and gather input related to the safe use of benzodiazepines. Participants will discuss epidemiological and abuse liability data, patient and clinician perspectives and experiences, and gaps in data and understanding about the safe use of benzodiazepines.

Day 1 Agenda

1:00 pm Welcome and Overview
   • Mark McClellan, Duke-Margolis Center for Health Policy

1:10 pm FDA Opening Remarks
   • Douglas Throckmorton, U.S. Food and Drug Administration

1:25 pm Session 1: Benzodiazepine Abuse Liability, Epidemiology, and Clinical Considerations
   Objectives:
   • Review available data and research on factors related to the abuse liability of benzodiazepines, including drug discrimination, self-administration, and clinical studies assessing reinforcing effects.
   • Discuss epidemiologic data on patterns of use and non-medical’ use of benzodiazepines, including use with other substances (i.e., polysubstance use) and associated harms
   • Understand clinical perspectives on benzodiazepine use, including treatment goals for benzodiazepine therapy

Presentations:
   • Chad Reissig, U.S. Food and Drug Administration
   • Jana McAninch, U.S. Food and Drug Administration
   • Kurt Kroenke, Indiana University School of Medicine

Questions and Answers

* The World Health Organization defines non-medical use of drugs as “taking of prescription drugs, whether obtained by prescription or otherwise, other than in the manner or for the reasons or time period prescribed, or by a person for whom the drug was not prescribed.” (link)
2:45 pm Break

3:00 pm Session 2: Clinical, Pharmacologic, and Public Health Perspectives

Objectives:
- Discuss the epidemiologic and abuse liability data, and identify remaining gaps in understanding of risks associated with use, misuse, and abuse of benzodiazepines
- Discuss whether there are differences among products within the class of benzodiazepines that may contribute to varying levels of risk for misuse or associated harms

Panel Discussion:
- **Wilson Compton**, National Institute on Drug Abuse
- **Carla Foster**, New York City Department of Health and Mental Hygiene
- **Anna Lembke**, Stanford University Medical Center
- **Naama Levy-Cooperman**, Altreos Research Partners
- **Kerri Schoedel**, Altreos Research Partners

4:25 pm Closing Remarks
- **Mark McClellan**, Duke-Margolis Center for Health Policy

4:30 pm Adjourn
Day 2 Agenda

1:00 pm  Welcome and Summary of Day 1
•  Mark McClellan, Duke-Margolis Center for Health Policy

1:10 pm  Session 3: Health Professional and Patient Advocate Perspectives – Best Practices, Experiences, and Concerns

Objectives:
•  Understand clinician-identified best practices, gaps in education, and other issues related to benzodiazepine prescribing and tapering
•  Discuss experiences of health professionals, patients, and caregivers with benzodiazepine initiation, short-term and long-term use, and tapering

Presentations:
•  Steven Wright, Alliance for Benzodiazepine Best Practices
•  Barbara Farrell, Bruyère Research Institute
•  Sangeeta Tandon, U.S. Food and Drug Administration

Panel Discussion
•  Chinyere Ogbonna, Kaiser Permanente
•  Sumit Agarwal, Brigham and Women’s Hospital
•  Christy Huff, Benzodiazepine Information Coalition
•  Steven Wright, Alliance for Benzodiazepine Best Practices
•  Barbara Farrell, Bruyère Research Institute
•  Scott Winiecki, U.S. Food and Drug Administration

2:45 pm  Break

3:00 pm  Session 4: Balancing the Benefits and Risks of Benzodiazepines

Objectives:
•  Discuss takeaways from information shared and gathered over the course of the workshop, including gaps in data and understanding

Panel Discussion
•  Kurt Kroenke, Indiana University School of Medicine
•  Wilson Compton, National Institute on Drug Abuse
•  Chinyere Ogbonna, Kaiser Permanente
•  Christy Huff, Benzodiazepine Information Coalition
•  Marc Stone, U.S. Food and Drug Administration
•  Marta Sokolowska, U.S. Food and Drug Administration

3:55 pm  Closing Remarks
•  Mark McClellan, Duke-Margolis Center for Health Policy

4:00 pm  Adjourn
Funding for this workshop was made possible in part by a cooperative agreement from the U.S. Food and Drug Administration Center for Drug Evaluation and Research. The views expressed in written workshop materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsements by the U.S. Government.